Skip to main content
ARQT
NASDAQ Life Sciences

Long-Term ZORYVE Data Published, Reinforcing Efficacy and Safety for Pediatric Atopic Dermatitis

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$24.81
Mkt Cap
$3.079B
52W Low
$11.86
52W High
$31.77
52W Position info
109% above low
Off High info
22% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ARQT has more than doubled off its 52-week low of $11.86.

Summary

Arcutis Biotherapeutics announced the publication of positive long-term safety and efficacy data for ZORYVE (roflumilast) Cream 0.05% in children aged 2-5 with mild-to-moderate atopic dermatitis in the journal Pediatric Dermatology. This data, from the Phase 3 open-label extension study, supported the FDA approval of ZORYVE for this indication in October 2025. The publication reinforces ZORYVE's profile, demonstrating maintained and improved efficacy over 56 weeks and a favorable safety profile, which is crucial for a chronic condition in a young patient population. This formal scientific validation adds credibility and can support broader physician adoption, strengthening the commercial outlook for a key product. Investors will continue to monitor the commercial rollout and sales performance of ZORYVE in this expanded pediatric indication.

At the time of this announcement, ARQT was trading at $24.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $11.86 to $31.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ARQT - Latest Insights

ARQT
Nov 05, 2026, 11:52 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $26.96
Real-time Price: $26.60 info
Change: -$0.360 (-1%) info
Market Cap: $3.394B info
ARQT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.00
Real-time Price: $26.60 info
Change: -$2.40 (-8%) info
Market Cap: $3.394B info
ARQT
Nov 04, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $26.60 info
Change: -$4.65 (-15%) info
Market Cap: $3.394B info
ARQT
Nov 04, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.30
Real-time Price: $26.60 info
Change: -$5.70 (-18%) info
Market Cap: $3.394B info
ARQT
Nov 04, 2026, 4:00 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $34.23
Real-time Price: $26.60 info
Change: -$7.63 (-22%) info
Market Cap: $3.394B info